Subscribe or Manage Preferences


By Wayne Kuznar San Diego, CA—Inadequate lupus-specific education and a lack of autoimmune centers are leading to a delay in the diagnosis of lupus, especially among ethnic minorities, who are disproportionately affected by lupus.
By Neil Canavan The new class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors may hold the key to more effective treatment for systemic lupus erythematosus (SLE), according to the results of a study just published in the peer-reviewed journal Arthritis & Rheumatism (Mina-Osorio P, et al. 2013;65:2380-2391).
By Rosemary Frei, MSc The diagnosis of systemic lupus erythematosus (SLE) is challenging, because of the heterogeneous nature of this disease. Early disease is especially challenging because patients often present with severe but uncharacteristic features. A team of rheumatologists has created a diagnostic algorithm based on the differential diagnosis of SLE (Bertsias GK, et al. Nat Rev Rheumatol. 2013 July 9 [Epub ahead of print]).
Page 3 of 5
Results 21 - 30 of 45
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology